

AASTROM BIOSCIENCES INC

FORM 8-K

(Current report filing)

Filed 08/02/10 for the Period Ending 08/02/10

Address	24 FRANKL LLOYD WRIGHT DR PO BOX 376 ANN ARBOR, MI 48106
Telephone	7349305555
CIK	0000887359
Symbol	ASTM
SIC Code	2836 - Biological Products, Except Diagnostic Substances
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	06/30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

August 2, 2010

Aastrom Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Michigan

000-22025

94-3096597

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

24 Frank Lloyd Wright Drive, P.O. Box 376,
Ann Arbor, Michigan

48106

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

(734) 930-5555

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01 Other Events.

2010 Annual Meeting Date

On August 2, 2010, Aastrom Biosciences, Inc. issued a press release announcing that it currently plans to hold its 2010 Annual Meeting of Shareholders (the "2010 Annual Meeting") on Thursday, October 21, 2010. Shareholders of record as of the close of business on August 26, 2010 will be entitled to notice of and to vote at the 2010 Annual Meeting. A copy of the press release, dated August 2, 2010, is filed herewith as Exhibit 99.1.

Shareholder Proposal and Nomination Deadline

The 2010 Annual Meeting date represents a change of more than 30 days from the anniversary of Aastrom's 2009 Annual Meeting of Shareholders. As a result, pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended, Aastrom has set a new deadline for the receipt of any shareholder proposals submitted pursuant to Rule 14a-8 for inclusion in the Company's proxy materials for the 2010 Annual Meeting. The new deadline for the submission of such shareholder proposals is the close of business on August 12, 2010. Such proposals should be delivered to: Aastrom Biosciences, Inc., 24 Frank Lloyd Wright Drive, P.O. Box 376, Ann Arbor, Michigan, 48106, Attention: Secretary. Aastrom recommends that such proposals be sent by certified mail, return receipt requested. Such proposals will also need to comply with the rules of the Securities and Exchange Commission regarding the inclusion of shareholder proposals in Aastrom's proxy materials, and may be omitted if not in compliance with applicable requirements.

Under Aastrom's current by-laws, proposals of business and nominations for directors other than those to be included in Aastrom's proxy materials following the procedures described in Rule 14a-8 may be made by shareholders if notice is timely given and if the notice contains the information required by Aastrom's by-laws. To be timely, a notice with respect to the 2010 Annual Meeting must be delivered to the Secretary of Aastrom no later than the close of business on August 12, 2010. Such proposals or nominations should be delivered to: Aastrom Biosciences, Inc., 24 Frank Lloyd Wright Drive, P.O. Box 376, Ann Arbor, Michigan, 48106, Attention: Secretary.

The description of the press release set forth herein does not purport to be complete and is qualified in its entirety by reference to the full text of the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

August 2, 2010

Aastrom Biosciences, Inc.

By: */s/ Timothy Mayleben*

Name: Timothy Mayleben

Title: Chief Executive Officer and President

Exhibit Index

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated August 2, 2010.

Aastrom Biosciences, Inc. Announces Date of 2010 Annual Meeting of Shareholders

Ann Arbor, Michigan, August 2, 2010 (11:30 am ET) — Aastrom Biosciences, Inc. (NASDAQ: ASTM) today announced that it currently plans to hold its 2010 Annual Meeting of Shareholders on October 21, 2010. Shareholders of record as of August 26, 2010 are entitled to notice of and to vote at the 2010 Annual Meeting of Shareholders.

About Aastrom Biosciences

Aastrom Biosciences is developing expanded autologous cellular therapies for use in the treatment of severe cardiovascular diseases. The company's proprietary cell-processing technology enables the production of cellular therapies expanded from a patient's own bone marrow and delivered directly to damaged tissues. Aastrom has advanced its cell therapies into late-stage clinical development, including a planned Phase 3 clinical program for the treatment of patients with critical limb ischemia and two ongoing Phase 2 clinical trials in patients with dilated cardiomyopathy. For more information, please visit Aastrom's website at www.aastrom.com.

Media contact

Stephen Zoegall
Berry & Company
212 253-8881
szoegall@berrypr.com

Investor Contact

Kimberli O'Meara
Aastrom Biosciences
734 930-5777
ir@aastrom.com

This document contains forward-looking statements, including without limitation, statements concerning clinical trial plans, objectives and expectations, clinical activity timing, intended product development, disease treatment and progression, patient symptoms and responses to treatment, treatment options and expected timing of collecting and analyzing treatment data, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "anticipates," "intends," "estimates," "plans," "expects," "we believe," "we intend," and similar words or phrases, or future or conditional verbs such as "will," "would," "should," "potential," "could," "may," or similar expressions. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with clinical trial and product development activities, regulatory approval requirements, competitive developments, and the availability of resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. These forward looking statements reflect management's current views and Aastrom does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.